Clinical Trials Logo

Clinical Trial Summary

This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any reason are able to enter the maintenance phase of this trial using daily gilteritinib


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05024552
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Contact Jhada-Kai Hunter
Phone 813-745-0286
Email Jhada-Kai.Hunter@moffitt.org
Status Recruiting
Phase Phase 1
Start date August 23, 2021
Completion date August 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05596981 - The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
Recruiting NCT05596968 - The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
Terminated NCT01028716 - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT05876832 - A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) Phase 3
Completed NCT03735875 - Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT01578109 - Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Phase 1
Completed NCT04788420 - Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
Recruiting NCT06222580 - SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Phase 1
Active, not recruiting NCT03333486 - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Phase 2
Terminated NCT02634827 - Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation Phase 2
Completed NCT01760655 - Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Phase 2
Recruiting NCT04174612 - AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance Phase 3
Completed NCT01253070 - Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Phase 2